In this study, we sought: (i) to characterize the mutational signatures of ER+/PR− breast cancers; (ii) to compare the molecular landscapes of PR− and PR+ Luminal tumors; and (iii) to define the prognostic value of the type and pattern of somatic genetic alterations in these patients. This evidence concerns the gene PGR and breast cancer.